Compare AbbVie Inc (ABBV) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $249.15 (market cap $438.19B), while YieldMax NVDA Option Income Strategy ETF trades at $12.8. The key difference: AbbVie Inc pays a 2.79% dividend while YieldMax NVDA Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | NVDY | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $263.58 | $17.96 |
52-Week Low | $197.38 | $11.58 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
NVDY trades at $13.00, up 1.72% with a bullish technical signal from moving averages. The ETF generates weekly dividend distributions ranging from $0.09 to $0.15, providing consistent income. Recent news highlights the fund's strategy of selling NVIDIA call options to fund distributions while potentially capping upside. Technical indicators show mixed signals with RSI at extreme levels suggesting potential overbought conditions.
The outlook balances income generation against opportunity cost. While weekly distributions offer attractive yield, the strategy may limit participation in NVIDIA's full growth potential. Key risks include the fund's dependence on NVIDIA's volatility and the trade-off between income and capital appreciation. Investors seeking regular income may find value, but those prioritizing growth might prefer direct NVIDIA exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
